Ultraconserved regions (UCRs) have been shown to originate non-coding RNA
transcripts (T-UCRs) that have different expression profiles and play functional roles
in the pathophysiology of multiple cancers. The relevance of these functions to the
pathogenesis of bladder cancer (BlCa) is speculative. To elucidate this relevance,
we first used genome-wide profiling to evaluate the expression of T-UCRs in BlCa
tissues. Analysis of two datasets comprising normal bladder tissues and BlCa
specimens with a custom T-UCR microarray identified ultraconserved RNA (uc.) 8+
as the most upregulated T-UCR in BlCa tissues, although its expression was lower
than in pericancerous bladder tissues. These results were confirmed on BlCa tissues by real-time PCR and by in situ hybridization. Although uc.8+ is located within
intron 1 of CASZ1, a zinc-finger transcription factor, the transcribed non-coding RNA
encoding uc.8+ is expressed independently of CASZ1. In vitro experiments evaluating
the effects of uc.8+ silencing, showed significantly decreased capacities for cancer
cell invasion, migration, and proliferation. From this, we proposed and validated a
model of interaction in which uc.8+ shuttles from the nucleus to the cytoplasm of
BlCa cells, interacts with microRNA (miR)-596, and cooperates in the promotion and
development of BlCa. Using computational analysis, we investigated the miR-binding
domain accessibility, as determined by base-pairing interactions within the uc.8+
predicted secondary structure, RNA binding affinity, and RNA species abundance
in bladder tissues and showed that uc.8+ is a natural decoy for miR-596. Thus
uc.8+ upregulation results in increased expression of MMP9, increasing the invasive
potential of BlCa cells. These interactions between evolutionarily conserved regions
of DNA suggest that natural selection has preserved this potentially regulatory layer
that uses RNA to modulate miR levels, opening up the possibility for development of
useful markers for early diagnosis and prognosis as well as for development of new
RNA-based cancer therapies